Literature DB >> 14744458

Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study.

Fanourios Kontos1, Maria Maniati, Christos Costopoulos, Zoe Gitti, Stavroula Nicolaou, Efymia Petinaki, Spyridoula Anagnostou, Ioannis Tselentis, Antonios N Maniatis.   

Abstract

The accuracy of the Bactec MGIT 960 system for susceptibility testing of 177 clinical isolates of Mycobacterium tuberculosis to first line drugs (isoniazid, rifampicin, ethambutol and streptomycin) was compared with the agar reference method. The sensitivity, the ability to detect resistance, of the MGIT system was 100%, while the specificity, the ability to detect susceptibility, ranged from 98.6% to 100% for all drugs tested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744458     DOI: 10.1016/j.mimet.2003.10.015

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  12 in total

1.  Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis.

Authors:  Meenu Sharma; Louise Thibert; Pamela Chedore; Cary Shandro; Frances Jamieson; Gregory Tyrrell; Sara Christianson; Hafid Soualhine; Joyce Wolfe
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

2.  Drug resistance patterns in 111 cases of drug-resistant tuberculosis spine.

Authors:  Kapil Mohan; Saurabh Rawall; Uday M Pawar; Meeta Sadani; Premik Nagad; Amita Nene; Abhay Nene
Journal:  Eur Spine J       Date:  2012-01-20       Impact factor: 3.134

3.  Does the MGIT 960 system improve the turnaround times for growth detection and susceptibility testing of the Mycobacterium tuberculosis complex?

Authors:  Akos Somoskovi; Anne Clobridge; Susan C Larsen; Oleg Sinyavskiy; Suheyla Surucuoglu; Linda M Parsons; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.

Authors:  Sreevalli Sharma; Ekaterina Gelman; Chandan Narayan; Deepa Bhattacharjee; Vijayashree Achar; Vaishali Humnabadkar; V Balasubramanian; Vasanthi Ramachandran; Neeraj Dhar; Neela Dinesh
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

7.  Comparison of the mycobacterium growth indicator tube method and the method of proportion for drug susceptibility testing of mycobacterium tuberculosis.

Authors:  Ayse Esin Aktas; Nimet Yigit; Ahmet Ayyildiz; Ayse Bastopcu
Journal:  Eurasian J Med       Date:  2014-06

Review 8.  Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.

Authors:  Louis Grandjean; David A J Moore
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

9.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

10.  Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Authors:  Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.